A Phase II study of docetaxel (T) and cyclophosphamide(C) as adjuvant chemotherapy for patients with high risk, node negative, early stage breast cancer
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000000493
- Lead Sponsor
- Japan East Cancer Center Breast Cancer Consortium
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- 50
Not provided
Male A history of other malignancies within the last 5 years except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix Bilateral breast cancer Inflammatory breast cancer A history of hypersensitivity reaction to drugs formulated with Polysorbate 80 Uncontrolled medical conditions (e.g., malignant hypertension, congestive heart failure, renal failure, myocardial infarction in the previous 6 months, treatment required arrhythmia, infection, hemorrhage) Grade 2-4 peripheral neuropathy Pleural or pericardial effusion requiring treatment Severe peripheral edema. Significant interstitial pneumonia or pulmonary fibrosis by CT scan or X-ray Patients who require concurrent treatment by corticosteroids except for premedication. Evere psychiatric disorders Pregnant or lactating women Patients judged by the investigator to be unfit to be enrolled into the study Prior chemotherapy or radiation therapy for other cancer within 3 years including neo-adjuvant chemotherapy for locally advanced breast cancer.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety, feasibility
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.